How did Shenzhen trial outcomes compare with patients not given Favipiravir?

Question

Accepted Answer

Shenzhen Trial Showed Favourable Outcomes for Patients Receiving Favipiravir

In a clinical trial conducted in Shenzhen, patients administered Favipiravir demonstrated notable improvements in chest condition and a reduced time to test negative for the virus's genetic material when compared to a control group that did not receive the drug. This trial involved a total of 80 participants.
Improved Chest Conditions Observed

The clinical trial in Shenzhen, which included 80 participants, found that individuals treated with Favipiravir experienced greater improvement in their chest condition. This suggests a positive impact of the drug on the respiratory symptoms associated with the illness.
Reduced Time to Viral Clearance

Furthermore, the same Shenzhen trial indicated that patients receiving Favipiravir took a shorter period to test negative for the genomic trace of the virus. This outcome points to a potential acceleration of viral clearance in patients treated with the drug.
Context of Favipiravir's Development and Approval

Favipiravir, also known by the brand name Avigan, is an anti-influenza drug developed by Fujifilm Toyama Chemical Co Ltd. It received approval for use in Japan in 2014. In China, Zhejiang Hisun Pharmaceutical Co Ltd has been approved to manufacture the drug for use against influenza. The drug has also been supplied by the Japanese government as emergency aid for the Ebola virus outbreak in Guinea in 2016.

Reading history

Hide →

This history is cleared when the page is closed.

How did Shenzhen trial outcomes compare with patients not given Favipiravir?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends